about
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsEZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsHELB Is a Feedback Inhibitor of DNA End ResectionDrug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.CopywriteR: DNA copy number detection from off-target sequence dataMEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression.Monitoring of tumor response to Cisplatin using optical spectroscopy.Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.Theileria-induced leukocyte transformation.Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopySelective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.Cancer cell death by programmed necrosis?Replication fork stability confers chemoresistance in BRCA-deficient cellsREV7 counteracts DNA double-strand break resection and affects PARP inhibitionImpact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.What makes tumors multidrug resistant?Modeling therapy resistance in genetically engineered mouse cancer models.BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1How do real tumors become resistant to cisplatin?Identifying subgroup markers in heterogeneous populations.Therapeutic options for triple-negative breast cancers with defective homologous recombination.Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.Drug resistance in the mouse cancer clinic.Minimal residual disease in cancer therapy--Small things make all the difference.Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice.The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.Intra-operative ex vivo photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion.Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.Hijacking of host cell IKK signalosomes by the transforming parasite Theileria.Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity.Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
P50
Q24599364-89F7F761-8AF6-4047-A9F6-3F5F84C8F523Q24632628-80071DA6-D94D-4C03-95FF-5FF5EC12B59BQ24644255-9AD7A12E-E6C3-4E76-B9CA-D49867206EAFQ27318449-5D2F5D46-5ACE-407B-A05B-D21D9499AEC9Q28115783-1D29AC2D-1808-4D71-B13D-217B730C1D1AQ30540353-31EAC542-D3D8-49C3-ABC1-67660C8AFF5AQ30936079-F7EAAD4D-BA0A-42D7-AD76-90BD29F12E73Q33739330-EC83E427-8A6A-4EA0-9E53-21B7A06E2DC4Q33912319-72DC836C-CB39-4604-94E8-82E7655522CDQ34500340-77EDB847-E9EF-4DFE-A12F-DA2A876C070FQ34619763-2B6A2CD5-E868-46C5-990A-B05EF71556ABQ35206906-78825B1D-9AAF-4269-B1C4-74572A4F5409Q35497704-1FE327B6-F4F6-4E93-8332-F0113D11F68EQ35845827-D65A3EEF-0006-4F0A-9C53-16B9F6CD2991Q35880493-A85B544A-F289-419E-A80E-1F145E949AC3Q36080028-CF37AF3D-444F-45B3-9014-B69C10AF4738Q36083474-72103DB5-980E-4ECA-A795-F7D23099D064Q36351056-1FB2ABA4-AAE3-47B7-AD6B-CFBF9F636C8DQ36456104-130EE47E-84A6-4FED-81C5-272B6C2FB1B4Q36653951-F3B61AEA-1B1F-475C-BFDA-688744469D27Q36832502-5A33BE21-8846-4455-8B5E-3546EF08CF56Q36999609-721237A3-94A2-47BE-8524-BBC8C0A62A77Q37047414-CC6992A4-B67F-4EF7-B522-574069AC4A37Q37137914-655C4D28-92FC-4FD2-A09C-1FD5C3BC65FFQ37140435-3323B30C-6F0F-4DC9-B869-66AB61AF2F91Q37327650-222977C4-6921-42DD-B41D-685AC61AC699Q37555542-3C21CFEA-FC9B-4A09-AD78-85061F74894AQ37665387-6F46BC0E-A423-438D-808B-F6236629BDABQ37984140-0D37139A-56A9-49E2-B2E7-EAC283CDB992Q38573896-655BC803-9008-41B7-8071-D57A3BDA0558Q38618043-6488DBB4-EA94-4935-B397-7189A8FD2FBEQ38750665-3679EC5F-D1A9-45E7-A622-83823F57B6FAQ38798405-C7527B2F-1C85-45D6-917A-9DB235A70DA4Q39206415-B62F79E6-9563-4469-98B9-27214E9F110CQ39252597-FA86D432-5F67-400B-91E9-FB8E4555889BQ40617502-17DEE1DE-F4D8-443F-9A86-5BE5CECB3944Q40692875-4A845148-33A3-4E61-8C91-BC529BFC2AD6Q41077638-BCF5CD34-2928-4750-9ADE-4AEB5810B8F6Q42446793-4C073274-F545-42DB-BED0-2088FDFBE3EBQ42467093-D11CA3B1-334A-4B02-BE4B-4D93D305905C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sven Rottenberg
@ast
Sven Rottenberg
@en
Sven Rottenberg
@es
Sven Rottenberg
@nl
type
label
Sven Rottenberg
@ast
Sven Rottenberg
@en
Sven Rottenberg
@es
Sven Rottenberg
@nl
prefLabel
Sven Rottenberg
@ast
Sven Rottenberg
@en
Sven Rottenberg
@es
Sven Rottenberg
@nl
P106
P1153
16025667800
P21
P31
P496
0000-0003-2044-9844